top of page

EU MDR Delay is (nearly) Official

  • Writer: Robert Bilkovski, MD
    Robert Bilkovski, MD
  • Apr 17, 2020
  • 2 min read

Ever since COVID-19 was declared by the WHO a global pandemic, medical device and in vitro diagnostics manufacturers were scrambling regarding MDR and IVDR readiness. COVID-19 has introduced significant impacts that affect product development timelines, including clinical trial execution and interactions with notified bodies.

Laboratory tests

The number of certified notified bodies has grown at a snails pace, that further challenges MDR (and IVDR) implementation. On March 25, 2020 the European Commission announced its intention to delay MDR implementation by one year. Moving the go-live date from May 2020 to May 2021. Today, MDR delay cleared a major hurdle in securing European Parliament approval. The Parliament vote of 693-1 (2 abstain) was compelling and now moves forward to securing approval by the member states. This news will provide relief to device manufacturers, given this time of uncertainty and afford an opportunity to refine and complete their MDR readiness activities.


Unfortunately, no further clarity has been rendered regarding delay of IVDR implementation, although many believe a one year delay is probable. Similar for IVD manufacturers, who are focusing their attention on providing solutions to address the COVID-19 pandemic, their attention for IVDR readiness may expose them to regulatory risk if IVDR regulation delay is not authorized. Therefore, it is essential to maintain focus on ensuring the technical file for each IVD will meet the General Safety and Performance Requirements (GSPR).


Central to meeting GSPR is to verify the scientific validity, analytical performance and clinical performance associated with each diagnostic test. IVD manufacturers should already be conducting performance gap assessments; if gaps are present, evidence plans should be designed and executed in the near future. Closure of the performance gap assessment culminates in the preparation of a performance evaluation report (PER) which includes the design of a post market performance follow-up (PMPF) plan.



Comments


  • Medical Device Innovators preparing for launch and clinical adoption

  • Diagnostics / IVD teams translating evidence into adoption

  • Biotech & Pharma teams supporting evidence-based education and sales

  • Investor-backed startups requiring credible clinical narratives for regulatory approval, launch and commercial growth

Who This is For

© 2025 by RNB Ventures Consulting, Inc.

    • LinkedIn Social Icon

    Why Physician-Led Matters

    We interpret science and translate that into a cogent and authentic story.

    Our work is led by physicians with decades of experience in medical affairs leadership, regulatory engagement, and clinical development inside global healthcare organizations.

    Physician Profile
    Robert Bilkovski, MD, MBA

    Dr. Bilkovski brings over two decades of leadership across medical affairs, clinical development, and regulatory strategy spanning medical devices, IVD, and pharmaceuticals.

    Former Medical Director roles include:

    • Becton Dickinson

    • Abbott Laboratories

    • GE Healthcare

    • Hospira (Pfizer)


    He is a subject-matter expert in Advertising & Promotion (AdPromo) and served as a panelist at RAPS Convergence addressing compliant clinical communication strategies.

    RBilkovski_2020-JAN.jpg

    Media Examples

    Physician Profile
    Joseph J. Pinzone, MD, MBA, FACP

    Dr. Pinzone combines academic medicine, industry leadership, and national media experience.

    Training:

    • NYU School of Medicine

    • Columbia-Presbyterian Medical Center (Internal Medicine)

    • Massachusetts General Hospital / Harvard Medical School (Endocrinology, NIH-funded research)


    Former Head of Medical Affairs at Amgen (XGEVA®). Hosted PBS programming and served as a national medical expert across television and digital media platforms.

    Headshot - Pinzone_edited_edited_edited.

    Media Examples

    Partnership with
    Good Chemistry Communications

    Good Chemistry Communications specializes in clinical publications and scientific content for pharmaceutical, biotechnology, medical device, and consumer products companies.

    Services include:

    • Clinical manuscript development for peer-reviewed journals

    • Evidence compendia for regulatory and reimbursement submissions

    • Conference abstracts, posters, and presentations

    • White papers and scientific summaries

    Eric Moorhead brings over 10 years of medical device and pharmaceutical experience, with a track record of successful publications in high-impact journals.

    bottom of page